Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4017 for skin 11β-HSD1 inhibition and wound healing in type 2 diabetes
2017-001351-31Phase 2Completed
- Sponsor
- University of Leeds
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing AZD4017 arm with Placebo arm (2 arms). Primary endpoint: 24 hour 11β-HSD1 activity in skin. Started Jun 2017; status: completed.
02
Drugs
AZD4017
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-001351-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001351-31.